Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The evolution of the psychedelic revolution

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82.

    CAS  Article  Google Scholar 

  2. Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol. Transl. Sci. 2020;4:563–7.

    Article  Google Scholar 

  3. Dunlap LE, Azinfar A, Ly C, Cameron LP, Viswanathan J, Tombari RJ, et al. Identification of psychoplastogenic N,N-dimethylaminoisotryptamine (isoDMT) analogues through structure–activity relationship studies. J. Med. Chem. 2020;63:1142–55.

    CAS  Article  Google Scholar 

  4. Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analog with therapeutic potential. Nature 2021;589:474–9.

    CAS  Article  Google Scholar 

  5. Lu J, Tjia M, Mullen B, Cao B, Łukasiewicz K, et al. An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress. Mol. Psychiatry. https://doi.org/10.1038/s41380-021-01159-1 (2021).

  6. Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, et al. Psychedelic-inspired drug discovery using an engineered biosensor. Cell. 2021;184:2779–2792. e18.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank all the members of the Olson Lab for helpful discussions.

Funding

This work was supported by funds from the National Institutes of Health (R01GM128997 to DEO, T32MH112507 to LPC) and Delix Therapeutics. David E Olson is a co-founder of Delix Therapeutics, Inc, serves as the chief innovation officer, is a member of the board of directors, and receives consulting fees. Delix Therapeutics has licensed technology from the University of California, Davis related to this manuscript. Lindsay P Cameron has nothing to disclose.

Author information

Authors and Affiliations

Authors

Contributions

The authors both contributed to the writing and editing of this manuscript.

Corresponding author

Correspondence to David E. Olson.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cameron, L.P., Olson, D.E. The evolution of the psychedelic revolution. Neuropsychopharmacol. 47, 413–414 (2022). https://doi.org/10.1038/s41386-021-01150-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41386-021-01150-y

Search

Quick links